Fzata, Inc.

We are honored to have been selected with these other great companies as a "Biopharma Industry Mover". We are getting closer everyday to making oral biologics a reality. Our mission is to transform patient safety, efficacy & access to biologics with BioPYM yeast micro-factories.

Breaking news! Fzata has been selected for a “Soapbox Presentation” at the upcoming 14th Annual Partnership Opportunities in Drug Delivery (#PODD2024) conference, Oct 28-29 in Boston. I’m looking forward to speaking on our game changing BioPYM oral platform for biologics delivery. Patient-friendly BioPYM fills a huge gap in oral non-injectable technologies for biologics. I can’t wait to share our IND stage development with the big pharma crowd! #drugdelivery  #partnershipopportunities #drugdevelopment #pharma

I am proud to have been able to represent #Fzata at the recent #IBDInnovate conference hosted by the Crohn's & Colitis Foundation. I met with so many amazing people working on cures, diagnostics, better designed clinical trials and patient support. The enthusiasm and determination of the people at the conference was both palpable and infectious (in a very good way!). Together we have accomplished much, but the mountain to climb is high! I am happy to share that Fzata is on the right track with our FZ006 therapeutic. I got a ton of positive feedback on our oral antiTNF-alpha. FZ006 checks a lot of boxes (High safety profile, GI-restricted, Locally active, Platform for expansion across disease states). I'm inspired to do what it takes to get this to the patients! Thank you Russell Wyborski for introducing me to this #IBDcommunity.

CBO of Fzata, Elizabeth Smith, discusses vision for Fzata in 2024. Recorded Live by The Bullpen on January 8th, 2024 during JPM Healthcare Conference.

Great news! Fzata was selected by #MarylandDepartmentofCommerce to join the delegation of Maryland companies to #BIO2024. We are thrilled to accept a Premier Access Registration to the convention June 3-6, 2024 in San Diego, CA.  Thank you to Commerce for the support and this outstanding opportunity to showcase Fzata!

Elizabeth Anne Smith, PhD MBA, Chief Business Officer at Fzata, Inc. will be joining the Bullpen at the Golden Gate Yacht Club in San Francisco January 8 - 10, 2024 for #JPM2024. Click below to schedule a meeting with Dr. Smith to discuss the latest in oral biologics and learn more about the BioPYM Platform and assets.

JPM is coming up and I am excited to hit the road and evangelize Fzata. In early January I will be at both BioTech Showcase and Bull Pen to talk with investors and strategic partners. The company has made great strides over the past 12 months for both the FZ002 C diff program and the FZ006 IBD program. First in human clinical trial for FZ002 is on schedule for 2024. It is incredibly exciting and fulfilling to be on the Fzata oral biologics team! This platform will be ground-breaking for safety, efficacy and access to biologics.